Article History
Received: 19 August 2016
Accepted: 21 December 2018
First Online: 15 February 2019
Competing interests
: The authors declare: a patent application has been submitted by the institutions INSERM and University of Montpellier, inventors Scrivo A. and Bomont P., under the number EP18306732.1 (status: pending). The patent application covers the use of Gigaxonin as a therapeutic target to modulate autophagy in diseases associated with altered autophagy.